Hikma Debuts ePHEDrine Injection in U.S.
Hikma launches ePHEDrine Sulfate Injection, 25 mg/5 mL, addressing anesthesia-related hypotension in the U.S.
Hikma Pharmaceuticals PLC (Hikma), a global leader in pharmaceuticals, has introduced ePHEDrine Sulfate Injection, USP in a 25 mg/5 mL dosage for the U.S. market. Delivered in a prefilled syringe, the product is designed to treat clinically significant hypotension during anesthesia.
Market Presence and Impact
According to IQVIA, sales of ePHEDrine Sulfate Injection, USP, 25 mg/5 mL, reached approximately $17 million in the U.S. during the 12 months ending October 2024.
Commitment to Patient Care
Hikma ranks among the top three suppliers of generic injectable medicines by volume in the U.S., offering over 170 essential medicines. The company continues to expand its portfolio, focusing on developing new dosage forms that improve healthcare accessibility and patient outcomes.
This launch highlights Hikma’s dedication to addressing critical medical needs and providing reliable, high-quality solutions for healthcare providers and their patients.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion